Value proposition

Advancing Diagnostics to the Point Of Care

Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners.

The Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway.

The Genedrive® CYP2C19 ID Kit empowers clinicians to make informed treatment decisions for stroke patients based on their individual ability to metabolise the antiplatelet clopidogrel.

Molecular diagnostics, point of care, pharmacogenetics, neonatal, IVD, healthcare, rapid testing, personalised medicine, genotyping, and IVD manufacturer